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Abstract  The  MHC  II  deﬁciency  is  a  rare  autosomal  recessive  primary  immunodeﬁciency  syn-
drome with  increased  susceptibility  to  respiratory  and  gastrointestinal  infections,  failure  to
thrive and  early  mortality.  This  syndrome  is  caused  by  mutations  in  transcription  regulators  of
the MHC  II  gene  and  results  in  development  of  blind  lymphocytes  due  to  the  lack  of  indica-
tory MHC  II  molecules.  Despite  homogeneity  of  clinical  manifestations  of  patients  with  MHC  II
deﬁciency, the  genetic  defects  underlying  this  disease  are  heterogeneous.  Herein,  we  report
an Iranian  patient  with  MHC  II  deﬁciency  harbouring  a  novel  mutation  in  RFXANK  and  novel
misleading clinical  features.  He  had  ataxic  gait  and  dysarthria  from  30  months  of  age.  Epidemi-
ology, clinical  and  immunological  features,  therapeutic  options  and  prognosis  of  patients  with paper.MHC II  are  reviewed  in  thisPlease  cite  this  article  in  press  as:  Farrokhi  S,  et  al.  MHC  class  II
Allergol  Immunopathol  (Madr).  2017.  http://dx.doi.org/10.101
©  2017  SEICAP.  Published  by  Else
∗ Corresponding author.
E-mail address: rezaei nima@tums.ac.ir (N. Rezaei).
http://dx.doi.org/10.1016/j.aller.2017.04.006
0301-0546/© 2017 SEICAP. Published by Elsevier Espan˜a, S.L.U. All rights deﬁciency:  Report  of  a  novel  mutation  and  special  review.
6/j.aller.2017.04.006
vier  Espan˜a,  S.L.U.  All  rights  reserved.
 reserved.
 IN PRESS+ModelA
2 S.  Farrokhi  et  al.
I
M
i
b
o
h
p
c
t
m
c
o
t
c
t
c
d
c
w
I
t
M
b
t
i
D
t
(
a
t
m
a
f
a
A
t
i
g
i
a
c
F
p
R
H
s
S
t
l
h
r
a
d
s
a
a
h
p
d
m
t
o
w
g
i
w
a
ﬁ
F
on  monocytes  and  on  B-cells.  Following  these  results,  theARTICLELLER-880; No. of Pages 13
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HC  II  deﬁciency  is  a  rare  autosomal  recessive  primary
mmunodeﬁciency  syndrome  (OMIM  number:  209920)  caused
y  mutations  in  the  genes  encoding  transcription  factors
f  MHC  II  genes.  Most  of  the  cases  of  MHC  II  deﬁciency
ave  been  reported  from  North  African  countries  with  a  high
revalence  of  consanguineous  marriages.1
Although  MHC  II  deﬁciency  is  less  profound  than  severe
ombined  immunodeﬁciencies  (SCID),  it  is  a  lethal  condi-
ion  that  is  associated  with  early  childhood  demise.  Clinical
anifestations  of  MHC  II  deﬁciency  are  similar  to  other
ombined  immunodeﬁciencies  and  are  comprised  of  early
nset  severe  respiratory  and  gastrointestinal  tract  infec-
ions,  failure  to  thrive  (FTT),  and  early  death.  Other
linical  manifestations  of  MHC  II  deﬁciency  include  sep-
icaemia,  neurological  symptoms,  and  rarely  autoimmune
ytopenia.2
CD4+  lymphopenia,  reversed  CD4+/CD8+  ratio,  and
ecreased  level  of  one  or  more  immunoglobulin  sub-
lasses  are  suggestive  of  MHC  II  deﬁciency,  particularly
hen  human  immunodeﬁciency  virus  infection  is  excluded.
mpaired  antigen-speciﬁc  antibody  production  and  delayed-
ype  hypersensitivity  are  other  immunological  features  of
HC  II  deﬁciency.  Although  the  deﬁnitive  diagnosis  is  made
y  genetic  analysis,  the  diagnosis  is  usually  made  based  on
he  absence  or  limited  expression  of  MHC  II  molecules  on
mmune  cells  using  ﬂow-cytometry.
MHC  II  deﬁciency  is  categorised  into  four  groups  of  A  to
,  based  on  the  affected  genes;  RFXANK  (Regulatory  fac-
or  X  associated  protein  containing  ankyrin  repeat), RFX5
Regulatory  factor  X-5),  RFXAP  (Regulatory  factor  associ-
ted  protein),  and  CIITA  (class  II  transactivator).  The  ﬁrst
hree  genes’  products  bind  to  the  X-box  of  the  MHC  II  pro-
oter  thereby  recruiting  a  general  transcription  factor  CIITA
nd  triggering  the  transcription  of  MHCII  gene  (Fig.  1).  Apart
rom  its  speciﬁc  transactivation,  CIITA  functionally  replaces
 basal  transcription  factor  TAF1  (TATA-Box  Binding  Protein
ssociated  Factor  1),  recruits  the  PIC  (preinitiation  complex)
o  the  core  promoter  and  with  its  acetyltransferase  activ-
ty  assures  a  proper  transcription  initiation  of  MHC  I  and  II
enes.3
Here  we  report  a  case  with  a  novel  homozygous  mutationPlease  cite  this  article  in  press  as:  Farrokhi  S,  et  al.  MHC  class  II
Allergol  Immunopathol  (Madr).  2017.  http://dx.doi.org/10.101
n  the  RFXANK  gene  followed  by  a  review  of  the  literature
bout  related  mutations  found  in  patients  with  MHC  II  deﬁ-
iency.
d
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Figure  1  Schematic  modigure  2  The  pedigree  of  the  patient.  The  index  patient  is
ointed  by  an  arrow.
eport
erein,  we  report  a  ﬁve-year-old  Iranian  boy  from  a  con-
anguineous  family  (Fig.  2) who  was  initially  diagnosed  with
CID  and  was  under  treatment  for  SCID.  He  was  referred
o  this  centre  because  of  the  normal  immunoglobulin  (Ig)
evels  which  were  inconsistent  with  the  SCID  diagnosis.  He
ad  experienced  episodes  of  fever,  protracted  diarrhoea  and
ecurrent  aphthous  lesions  in  his  mouth  from  four  months  of
ge.  He  had  not  been  vaccinated  after  four  months  of  age
ue  to  the  early  diagnosis  of  SCID.  He  had  later  developed
evere  upper  respiratory  infections.  He  suffered  from  FTT
nd  developmental  delay  as  he  did  not  reach  the  growth
nd  developmental  milestones  on  the  expected  timeline.  He
ad  sat  since  18  months  of  age  and  had  walked  without  sup-
ort  when  he  was  30  months.  His  gait  was  ataxic  and  he  had
ysarthria.
Providing  the  patient’s  familial  history,  the  patient’s
other  gave  birth  to  a  dead  female  foetus.  Unfortunately,
here  is  no  evidence  of  the  foetus’s  genetic  analysis.  More-
ver,  the  patient’s  uncle  (mother’s  brother)  died  of  a  disease
ith  similar  symptoms  in  his  childhood.  The  patient’s  pedi-
ree  is  illustrated  in  Fig.  2.
Laboratory  ﬁndings  revealed  low  CD4+ T  cell  count  and
nverted  CD4/CD8  ratio  (Table  1).  Although  total  Ig  levels
ere  normal,  decreased  IgA  level  was  detected.  Increased
ntibody  level  observed  after  pneumococci  vaccination  con-
rmed  normal  immunity  response  to  conjugate  vaccines.
low  cytometry  revealed  no  expression  of  MHC  II  antigen deﬁciency:  Report  of  a  novel  mutation  and  special  review.
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iagnosis  of  MHC  II  deﬁciency  was  made.
Next  generation  sequencing  targeting  the  known  primary-
mmunodeﬁciency  genes  from  International  Union  of
el  of  MHC  II  promoter.
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Table  1  Immunological  features  of  the  patient  with  the  associated  normal  range  in  this  patient’s  age  group.  white  blood  cells
(WBC), immunoglobulin  (Ig).
Patient  data  Normal  range  Unit
Cell  count
WBC  8180  4000--11,000  /mm3
Lymphocyte  60  20--40  %
Platelet 433,000  150,000--450,000  /mm3
Ig  concentration
IgG  916  500--1450  mg/dL
IgA 2  30--200  mg/dL
IgM 42  25--200  mg/dL
Immunophenotyping
CD3 76  60--77.5  %
CD4 11  31--47.5  %
CD8 61  16--27  %
CD4/CD8 ratio  0.18  1.3--3
CD19 13  13--29  %
CD16 4  4.5--16  %
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mImmunological  Societies  20144 revealed  a  homozygous  muta-
tion  in  RFXANK  gene  on  chromosome  19p12.  The  mutation
is  a  G  to  A  substitution  in  TGG  codon  for  W188,  leading  to
a  premature  stop  codon  in  exon  3.  Combined  Annotation
Dependent  Depletion  (CADD)  score,  which  is  a  measure  of
the  deleteriousness  of  single  nucleotide  variants,  is  35.00
for  this  mutation.  The  mutation  was  conﬁrmed  by  Sanger
analysis  and  it  showed  a  perfect  segregation  with  the  par-
ents.
Even  though  the  patient  was  admitted  and  intravenous
antibiotic  treatment  was  initiated,  he  died  of  pneumonia
and  septicaemia.
Discussion
MHC  II  deﬁciency  is  classiﬁed  according  to  the  MHC  II
molecule  expression  after  pairwise  fusion  of  different
patient  cell  lines.  The  complementation  groups  were  named
by  their  order  of  discovery.  There  have  been  four  comple-
mentation  groups  since  1997,  when  Durand  et  al.  introduced
MHC  II  deﬁciency  group  D  with  defects  in  RFXAP  gene.5 More
than  half  of  the  patients  with  MHC  II  deﬁciency  have  muta-
tions  in  RFXANK,  which  are  categorised  as  Group  B.  In  this
paper,  we  reported  a  novel  mutation  in  RFXANK  gene  that
caused  MHC  II  deﬁciency  in  an  Iranian  boy.  Moreover,  we  per-
formed  a  systematic  literature  review  to  ﬁnd  all  reported
mutations  causing  MHC  II  deﬁciency.  The  authors  searched
English  language  literature  using  PubMed  search  engine  with
key  words  of  ‘‘MHC  class  II  deﬁciency’’  and  ‘‘Bare  lympho-
cyte  syndrome’’  up  to  August  2016.  The  data  were  extracted
from  those  studies  with  a  reported  mutation  in  patients  or
cell  lines.  Cases  without  mutation  analysis  were  excludedPlease  cite  this  article  in  press  as:  Farrokhi  S,  et  al.  MHC  class  II
Allergol  Immunopathol  (Madr).  2017.  http://dx.doi.org/10.101
from  this  study.  Here,  we  present  each  study  with  asso-
ciated  mutations,  ethnicity  and  clinical  symptoms  in  four
tables  regarding  each  group  individually.  The  results  of  this
systematic  search  have  been  presented  in  Tables  2--5.
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he  geographic  distribution  of  MHC  II  deﬁciency  is  con-
ned  to  areas  with  a  high  prevalence  of  consanguineous
arriages.  Thus  MHC  II  deﬁciency  is  more  prevalent  in
iddle  European  countries,  Middle  Eastern  countries  and
frican  countries,  with  the  highest  prevalence  observed  in
editerranean  areas.6 Of  103  reported  patients  with  MHCII
hose  ethnicity  is  known,  94  (91.2%)  come  from  Asian,
iddle-East  or  African  families  (Tables  2--5).  These  regions
ave  a  high  prevalence  of  consanguineous  marriages,  which
ncreases  the  incidence  of  autosomal  recessive  disorders
ue  to  the  limited  gene  pool.  Group  B  MHC  II  deﬁciency
s  more  concentrated  in  North  African  areas  and  Group  A
eems  to  be  more  prevalent  in  European  countries.  Herein
e  report  the  ﬁrst  Iranian  patient  with  group  B  MHC  II
eﬁciency.
Although  MHC  II  deﬁciency  is  considered  as  a  related
CID  disorder,  almost  none  of  the  patients  developed
he  ﬁrst  manifestations  around  birth.  There  is  a  con-
iderable  time  gap  between  the  onset  of  infections  and
he  diagnosis.  This  diagnostic  gap  has  been  elucidated
n  several  studies  on  patients  with  group  B  MHC  II  deﬁ-
iency.  The  mean  age  at  the  time  of  the  ﬁrst  presentation
as  4.2--10  months  of  age7--10 and  the  mean  age  at  the
ime  of  diagnosis  was  21--42  months  of  age.8--10 Thus,
here  has  been  a  17--32-month  diagnostic  gap  in  reported
ases.  This  diagnostic  gap  may  be  due  to  the  non-speciﬁc
r  less  severe  manifestations  at  the  beginning  of  the
isease.
In  this  patient,  despite  the  early  onset  of  disease  at  four
onths  of  age,  the  syndrome  was  diagnosed  at  ﬁve  years deﬁciency:  Report  of  a  novel  mutation  and  special  review.
6/j.aller.2017.04.006
f  age,  which  is  remarkably  higher  than  the  mean  age  of
iagnosis  in  other  studies  and  that  may  be  because  of  the
atient’s  unusual  clinical  presentation,  which  is  discussed
ater  in  the  text.
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Table  2  Group  A  mutations.  Not  determined  (ND),  number  (N.),  patients  (Pts).
N.  Study  Mutation  Effect  N.  of
Pts
Ethnicity  Other  ﬁndings  Clinical  features  Treatment  Outcome  Ref.
1  Dimitrova
et  al.  (2014)
Homozygous  c.3317  +  1
G  >  A
--  1  Mexican
--Iranian
Coincident  Xq28
microdeletion  --
diverse  parental
ethnicity
Disseminated  M.
avium  complex,  mild
intellectual  disability
Supportive
care
ND 2
2  Schmetterer
et  al.  (2010)
Homozygous  p.  Glu381X  Nonsense  mutation  in  exon  11
leading  to  loss  of  the
C-terminal  nuclear  localisation
domain  --  impaired  binding  of
CIITA  to  enhanceosome
1  Austrian  VIP1  cell  line  Acute  viral
bronchiolitis  and
pneumonia
ND  ND 16
3  Dziembowska
et  al.  (2002)
Heterozygous  c.G2178A
(p.  Trp  to  X)
Paternal  allele:  only
silent  mutations
1  ND  SP  cell  line  Chronic  diarrhoea,
respiratory  infections
HSCT  Died  of
GVHD  or
infection
14
4  Dziembowska
et  al.  (2002)
Allele  1:  del3003--3084
Allele  2:  CATdel3193--5
Allele  1:  exon  skipping
between  Leu964  and  Asp991
(27  aa)
1  ND  RC  cell  line  Chronic  diarrhoea,
respiratory  infections
HSCT  Died  of
CMV
infection
14
5  Dziembowska
et  al.  (2002)
No  mutations  in  neither
coding  nor  non-coding
regions
Probably  mutated  stabilising
region  or  regulatory  sequence
1  ND  OK  cell  line  Chronic  diarrhoea,
respiratory  infections
HSCT  Died  of
GVHD  or
infection
14
6  Wiszniewski
et  al.  (2001)
Homozygous  c.T1524C
(p.  L469P)
Missense  mutation  in
N-terminal  end  of  LCD  motif
which  is  essential  for  CIITA
activity
3  Greek  Siblings  --  Sa  cell
line
Pneumonia,
septicemia,  recurrent
respiratory
infections,  recurrent
gastroenteritis
Supportive
care
Alive 27
7  Peijnenburg
et  al.  (2000)
Homozygous  c.  84bp  del
3265--3348
Splice  donor  site  mutation
results  in  28-aa  truncated
protein
1  Turkish  ATU  cell  line  ND  ND  ND 28
8  Quan  et  al.
(1999)
Homozygous  p.  F961S  Missense  mutation  leading  to
an inactive  protein
1  ND  Late  presentations
(twenties)  --  Fern
cell  line
Multiple  bacterial
infections
ND  ND 29
9  Fondaneche
et  al.  (1998)
Not  evaluated  1  Pakistani  Recurrent  infections,
severe  diarrhoea  and
failure  to  thrive
ND  ND 30
10  Bontron
et  al.  (1997)
Mannhalter
et  al.  (1991)
Allele  1:  c.G1256T  (p.
E381X)
Allele  2:  84bp
del3349--3432/p.  D1078E
Allele  1:  nonsense  mutation  in
exon  11  leading  to  loss  of  the
C-terminal  nuclear  localisation
domain  --  impaired  binding  of
CIITA  to  enhanceosome
1  Austrian  Second  case  of
group  A  with  two
novel  mutations  --
BCH  cell  line
ND  ND  ND 15,31
11  Steimle
et  al.  (1993)
Homozygous
c.  72bp  del2932-3003
Exon  skipping  --  24-aa
truncated  protein
1  ND  BLS-2  cell  line  ND  ND  ND 13,32
Please
 cite
 this
 article
 in
 press
 as:
 Farrokhi
 S,
 et
 al.
 M
H
C
 class
 II
 deﬁciency:
 Report
 of
 a
 novel
 m
utation
 and
 special
 review
.
Allergol
 Im
m
unopathol
 (M
adr).
 2017.
 http://dx.doi.org/10.1016/j.aller.2017.04.006
A
RTICLE IN PRESS
+M
odel
ALLER-880;
 
N
o.
 of
 Pages
 13
M
H
C
 class
 II
 deﬁciency
 
5
Table  3  Group  B  mutations.  Not  determined  (ND),  failure  to  thrive  (FTT),  HPV  (human  papilloma  virus),  number  (N.),  patients  (Pts).
N.  Study  Mutation  Result N.  of  Pts Ethnicity  Other  ﬁndings Clinical  features Treatment Outcome  Ref.
1  Ben-Mustapha
et  al.  (2013)
Homozygous
c.  752delG26bp
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
25  Tunisian Largest  study  on  a
Maghrebian
country  (34
individuals  of  28
families)  -- 22
families  were
consanguineous
Chronic  diarrhoea,
pulmonary  infections,
failure  to  thrive
Less  frequent:  dysmorphic
features,  hepatic
involvement,  Oral  HPV,
Septicaemia,  purulent
otitis,  neurologic
manifestations
4  HSCT
21  sup-
portive
care
4  died
14  died
9
2  Djidjik  et  al.
(2012)
Homozygous
c.  752delG26bp
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
9  Algerian
Kabylian
Consanguineous
families  in  8  out  of
11  families
Diarrhoea,  recurrent
respiratory  infections,  FTT
Less  frequent:  genitourinary
infections,  thrush,  eczema,
Molluscum  contagiosum
Supportive
care
1  died
due  to
septi-
caemia
8
3  Guirat-Dhouib
et  al.  (2012)
Homozygous
c.  752delG26bp
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
2  Tunisian  Siblings  Recurrent
bronchopulmonary  and
gastrointestinal  infections,
late  oral  HPV  infection
Supportive
care
ND 33
4  Ouederni  et  al.
(2011)
Homozygous
c.  752delG26
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
13  Algerian
Moroccan
A  study  of  13  new
and  22  previously
reported  patients
Protracted  diarrhoea,
bronchopulmonary
infections,  FTT,  liver
disease
6  HSCT
6  sup-
portive
care
2  died
1 died
10
5  Naamane  et  al.
(2010)
Homozygous
c. 752delG26
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
10  Moroccan  Consanguineous
parents  in  8  of  10
Pts,
Recurrent  respiratory  tract
infection,  recurrent
diarrhoea,  pneumonia,
mucocutaneous  candidiasis
ND  ND 7
6  Prod’homme
et  al.  (2003)
Homozygous
c.  IVS4  +  5G  >  A
Prevents  splicing  in
intron  4  and  5
1  Jewish/Egyptian  First  moderate
case  of  the  disease
-- SM  cell  line
Sepsis,  recurrent
pneumonias,  chronic
diarrhoea,  FTT
ND  ND 34
7  Wiszniewski
et  al.  (2003)
Homozygous
p.  D121V
Missense  mutation  in
exon  6
1  Saudi  Arabian  --  Recurrent  infections,  severe
diarrhoea  and  failure  to
thrive
ND  ND 18
8  Wiszniewski
et  al.  (2003)
Homozygous
p.  R212X
Nonsense  mutation  in
exon  9--48  residue
truncation
1  Turkish  --  Recurrent  infections,  severe
diarrhoea  and  failure  to
thrive
ND  ND 18
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Table  3  (Continued)
N.  Study  Mutation  Result  N.  of  Pts  Ethnicity  Other  ﬁndings  Clinical  features  Treatment  Outcome  Ref.
9  Lennon-
Duménil  et  al.
(2001)
Homozygous
c.  IVS4  +  1G  >  C
p.  del28aa
Lack  of  exon  4  1  North  Africa  JER  cell  line  --
consanguineous
family
Severe  chronic  diarrhoea,
recurrent  pulmonary
infections,  and
mucocutaneous  candidiasis
ND  ND 35
10  Wiszniewski
et  al.  (2000)
Homozygous
c.752delG-25
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
17  Algerian  (9)
Kabylian  (3)
Tunisian  (3)
Moroccan  (1)
Algerian/French
(1)
13/15
consanguineous
Recurrent  respiratory  tract
infection,  recurrent
diarrhoea
ND  ND 17
11  Wiszniewski
et  al.  (2000)
Homozygous
p.  E101X
Premature  stop  codon
in  exon  5--158  residue
truncation
1 Turkish  --  Recurrent  respiratory  tract
infection,  recurrent
diarrhoea
ND  ND 17,18
12  Wiszniewski
et  al.  (2000)
Homozygous
p.  R156X
Premature  stop  codon
in  exon  7--105  residue
truncation
1  Italian  --  Recurrent  respiratory  tract
infection,  recurrent
diarrhoea
ND  ND 17,18
13  Wiszniewski
et  al.  (2000)
Heterozygous
Allele  1:
c.797delT
Allele  2:  c.
856-1G  >  T
Deletion  in  exon  6
leading  to  frameshift
and  27  KD  truncated
prt  --  exon  6--7
skipping
1  French/Spanish  Not
consanguineous
Recurrent  respiratory  tract
infection,  recurrent
diarrhoea
ND  ND 17,18
14  Nagarajan
et  al.  (2000)
Homozygous
p.  L195P
Missense  mutation  in
exon  8  in  the  third
ankyrin  repeat
1  ND  FZA  cell  line  ND  ND  ND 36
15  Nagarajan
et  al.  (2000)
Homozygous
p.  Q103X
Nonsense  mutation  in
exon  5  --  truncated
prt
1  ND  EBA  cell  line  ND  ND  ND 36
16  Nagarajan
et  al.  (2000)
Homozygous
c.  752delG26bp
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
1  ND  Ramia  cell  line  ND  ND  ND 36,37
17  Nagarajan
et  al.  (1999)
Homozygous
c.  752delG26bp
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
2  ND  Nacera  and  Bequit
cell  lines
ND  ND  ND 38
18  Masternak
et  al.  (1999)
Homozygous
c.  752delG26bp
Excision  of  exons  5
and  6,  premature
stop  codon  in  exon  9
3  ND  Na,  Ab  and  BLS1
cell  line
ND  ND  ND 39
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Table  4  Group  C  mutations.  DNA  binding  domain  (DBD),  not  determined  (ND),  number  (N.),  patients  (Pts).
N.  Study  Mutation  Result N.  of  Pts Ethnicity  Other  ﬁndings Clinical
features
Treatment Outcome  Ref
1  Nekrep  et  al.
(2002)
Homozygous
c.  446G  >  A  (p.  R149Q)
Missense  mutation  in
DBD  leading  to  impaired
DNA-binding  ability
2  ND  Ker  cell  line ND  ND  ND 40
1  Peijnenburg
et  al.  (1999)
Homozygous
c.  1122  C  >  T  (p.  Q321X)
320-aa  truncated  protein
that  still  contains  the
DNA-binding  domain  but
is inactive
1  Dutch-
Indonesian
SSI  cell  line ND  ND  ND 41
2  Peijnenburg
et  al.  (1999)
Homozygous
c.  4ntdel  312--315(CAAG)
fsX403--405
Splice  acceptor  site
mutation  leading  to
82-aa  truncated  protein
which  lacks  the  DBD
1  Turkish OSE  cell  line ND  ND  ND 42
3  Villard  et  al.
(1997)
Homozygous
c.  10ntdel259--268fsX334
Mutation  in  splice  donor
site,  utilisation  of
cryptic  splice  site
2  ND  TVF/EHF
siblings--consanguineous
parents
ND  ND  ND 43
4  Steimle  et  al.
(1995)
Allele  1:  c.  5Nt  del
386--390  fsX410
Allele  2:  wild  type
Truncated  non-functional
protein
1  ND  SJO  cell  line ND  ND  ND 44
5  Steimle  et  al.
(1995)
Homozygous
c.  1032  C  >  T  (p.  R  >  X)
c.  1378  C  >  G  (p.  P  >  R)
Severely  truncated
protein
1  ND  Ro  cell  line  ND  ND  ND 44
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Table  5  Group  D  mutations.  Amino  acid  (aa),  not  determined  (ND),  cytomegalovirus  (CMV),  number  (N.),  patients  (Pts).
N.  Study  Mutation  Effect  N.  of  Pts  Ethnicity  Other  ﬁndings  Clinical  features  Treatment  Outcome  Ref.
1  Schmetterer
et  al.  (2010)
Homozygous
p.  Ser123ThrfsX15
Mutation  in  exon  1
leading  to  a  premature
stop  codon  --
non-functional  protein
1  Austrian  Unrelated
parents  --
VIP2  cell  line
Recurring  CMV  and
adenovirus  respiratory
infections,  Pneumocystis
jirovecii  pneumonia
ND  ND 16
2  Van  Eggermond
et  al.  (2008)
Homozygous  75bp
insertion  in  5′-UTR
Insertion  in  5′-UTR  of
exon  1  --  prohibits
transcription
1  Turkish  --  Recurrent  respiratory
system  infections,
persistent  diarrhoea  and
otitis  media  with
malnutrition
ND  ND 45
3  Fondaneche
et  al.  (1998)
Homozygous
c.  delG484fsX525
Severely  truncated  and
inactive  protein  of  only
136  aa
2  North  African  SS  family  cell
line
Prolonged  diarrhoea,
respiratory  infections
ND  ND 30
4  Fondaneche
et  al.  (1998)
Homozygous
c.  279C  >  G  (p.  Q  >  X)
52-aa  truncated  protein  1  Turkish  AkO  cell  line  Prolonged  diarrhoea,
respiratory  infections
ND  ND 30
5  Fondaneche
et  al.  (1998)
Homozygous
c.
151ins7(GCGGGCG)fs329X
136-aa  truncated  protein  2  Druze  Cousins  --  ShA
and  ShG  cell
lines
Prolonged  diarrhoea,
respiratory  infections
ND  ND 30
6  Villard  et  al.
(1997)
Homozygous
c.  279  C  >  G  (p.  Q  >  X)
52-aa  truncated  protein  1  Turkish  ABI  cell  line  ND  ND  ND 46,47
7  Villard  et  al.
(1997)
Homozygous
c.  delG484fsX525
Severely  truncated  and
inactive  protein  of  only
136  aa
1  Algerian  ZM  cell  line  ND  ND  ND 46,47
8  Durand  et  al.
(1997)
Homozygous
c.  delG484fsX525
Severely  truncated  and
inactive  protein  of  only
136  aa
1  Moroccan  DA  cell  line  ND  ND  ND 5
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MHC  class  II  deﬁciency  
Clinical ﬁndings
Similarly,  in  all  four  complementation  groups  we  did  not
notice  any  signiﬁcant  difference  in  clinical  manifestations.
Almost  all  of  the  patients  develop  respiratory  and  gas-
trointestinal  infections  several  months  prior  to  making  the
diagnosis  of  MHC  II  deﬁciency.  Diffuse  and  severe  infections
of  gastrointestinal,  cutaneous  and  respiratory  origin  with
rare  pathogens  are  common  ﬁndings  in  patients  with  MHC  II
deﬁciency.  Other  less  frequent  manifestations  are  FTT,  intel-
lectual  disability,  transaminitis  and  neurological  symptoms,
septicaemia  and  autoimmune  cytopenias.  The  non-speciﬁc
clinical  presentation  of  the  disease  may  be  a  reason  for  the
prolonged  lag  of  diagnosis  from  the  onset  of  manifestations.
The  clinical  features  in  group  B  patients  are  more  diverse.
There  are  some  unique  presentations  which  are  not  reported
in  other  groups  e.g.  dysmorphic  features,  transaminitis,  oral
HPV  and  candidiasis,  thrush,  purulent  otitis,  neurological
manifestations,  genitourinary  infections,  eczema  and  Mol-
luscum  contagiosum.8,9 The  exclusive  manifestation  of  these
symptoms  in  patients  with  group  B  MHC  II  deﬁciency  should
be  further  studied.
In  addition  to  the  classical  clinical  features  observed  in
patients  with  MHC  II  deﬁciency,  the  patient  reported  here
had  several  new  manifestations  that  may  be  worth  study-
ing  more  carefully  for  their  relevance  to  the  BLS  syndrome.
One  major  presentation  was  recurrent  oral  aphthous,  which
have  not  yet  been  reported  in  the  literature.  Previously,
oral  ulcers  were  reported  in  a  ﬁve-year-old  boy  with  MHC
II  deﬁciency  from  a  non-consanguineous  marriage  between
an  Iranian  father  and  an  American-Mexican  mother.2 More-
over,  the  patient  suffered  from  two  neurological  disabilities,
dysarthria  and  ataxic  gait.  These  heterogeneous  clinical
features  might  be  misleading  in  the  early  diagnosis  of  the
disease.
Immunological features
There  are  no  speciﬁc  differences  in  laboratorial  ﬁndings
in  patients  of  different  groups.  Although  the  common
immunophenotype  is  CD4+ lymphopenia  with  reversed
CD4/CD8  ratio,1 a  patient  with  MHC  II  deﬁciency  was
reported  to  have  normal  CD4/CD8  ratio  due  to  the  decreased
CD8+ count.11 The  CD4+ lymphopenia  is  a  result  of  impaired
MHC  II-dependant  thymic  maturation  of  T  cells.1 Serum
immunoglobulin  subclasses  are  variable  and  may  be  normal,
decreased  or  increased.  The  count  of  B  cells  and  NK  cells
are  normal  in  most  cases.  Since  the  immune  response  to
foreign  antigens  is  impaired,  patients  with  MHC  II  deﬁciency
fail  to  develop  a  proper  active  immunity  by  vaccination.
However,  the  immunodeﬁciency  is  not  severe  enough  to
develop  disseminated  infections  after  vaccination.  Thus,
patients  with  MHC  II  deﬁciency  are  vaccinated  according  to
the  national  vaccination  programme  in  their  country  of  res-
idence.  There  is  one  reported  case  of  disseminated  BCGitis
in  a  patient  who  was  later  diagnosed  to  have  probable  MHC
II  deﬁciency.12 Moreover,  another  patient  of  group  A  MHCPlease  cite  this  article  in  press  as:  Farrokhi  S,  et  al.  MHC  class  II
Allergol  Immunopathol  (Madr).  2017.  http://dx.doi.org/10.101
II  deﬁciency  developed  symptomatic  varicella  after  vaccine
administration.2
The  main  immunological  ﬁndings  in  the  presented  patient
were  low  CD4+ T  cell  count  and  inverted  CD4/CD8  ratio.
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here  was  only  a decline  in  IgA  level  and  other  immunoglob-
lin  levels  were  in  normal  limits.  Because  of  the  unique
resentation  of  the  disease  and  early  diagnosis  of  SCID,  the
atient  was  not  vaccinated  after  four  months  of  age.  But
uring  his  referral  to  our  centre,  the  patient  showed  normal
esponse  to  conjugated  vaccines  due  to  the  fourfold  increase
n  anti-pneumococcal  antibody  after  vaccination.
utation analysis
he  list  of  mutations  underlying  MHC  II  deﬁciency  is  growing.
t  sheds  light  on  the  pathophysiology  of  disease  and  opens
ew  windows  to  immunologists  studying  primary  immunode-
ciencies.  Here  we  added  a  novel  mutation  in  RFXANK  gene,
hich  is  categorised  as  group  B  of  MHC  II  deﬁciency.  This
utation  similar  to  others  leads  to  decreased  MHC  II  tran-
cription  and  thereby  MHC  II  expression  by  immune  cells
hich  are  illustrated  in  Fig.  1. Identiﬁcations  of  genetic
efects  underlying  MHC  II  deﬁciency  can  be  of  value  for
argeted  gene  therapy  - which  is  a  dream  at  the  moment.
The  ﬁrst  described  MHC  II  deﬁciency  disease-causing
ene  was  CIITA,13 a  28-exon  gene  located  on  16p13  locus.
here  are  three  isoforms  of  CIITA,  all  having  a Leucine-rich
otif  (LRM)  participating  in  protein--protein  interactions.
he  LRM  is  located  in  residues  790--1115,  789--1114  and
99--530  of  the  three  isoforms  respectively.  To  the  best  of
ur  knowledge,  approximately  12  different  mutations  have
een  reported  (Table  2).  The  mutations  either  lead  to  a
remature  stop  codon  resulting  in  a  truncated  protein  or
re  missense  mutations  resulting  in  inactive  proteins.  Most
f  the  defected  CIITA  proteins  are  unable  to  bind  to  the
nhanceosome  complex  in  the  promoter  of  MHC  II  gene
ecause  the  LRM  is  involved.  There  is  only  one  patient  with
o  mutations  in  the  coding  and  non-coding  areas  of  CIITA
ene.14 The  mutation  is  suspected  to  be  in  the  regulatory
reas  upstream  of  the  CIITA. There  were  two  unrelated
ustrian  patients  with  the  same  nonsense  p.  E381X  muta-
ions,  suggesting  a  possible  association  of  this  mutation  with
ustrian  ethnicity.15,16 There  was  also  one  patient  with  a  het-
rozygous  mutation  with  only  null  mutations  in  one  allele.14
Group  B  MHC  II  deﬁciency  with  mutations  in  RFXANK  gene
as  the  second  to  be  discovered.  RFXANK  gene  is  located  on
9p12  locus  with  12  exons  in  its  transcript.  There  are  sev-
ral  isoforms  of  RFXANK  proteins  differing  in  the  number  of
nkyrin  repeats,  which  are  the  protein--protein  interaction
ites  crucial  for  binding  to  other  RFX  proteins.  Each  repeat
ontains  two  antiparallel  helices  and  a  beta-hairpin  and  is
tacked  in  a  superhelical  arrangement  coupled  with  other
epeats.  Generally,  there  have  been  11  reported  mutations
n  group  B  BLS  patients  that  affect  exons  4--9  of  the  RFX-
NK.  Except  two  missense  mutations  in  exons  6  and  8,  the
emainder  result  in  truncated  proteins  or  excision  of  one  or
ore  exons.  All  of  the  reported  mutations,  either  nonsense
r  splice-site  mutations,  result  in  proteins  lacking  either  a
art  or  all  of  the  ankyrin  repeats.
The  most  frequent  mutation  in  group  B  MHC  II  deﬁ-
iency  patients  is  a  752delG26  leading  to  excision  of  exons deﬁciency:  Report  of  a  novel  mutation  and  special  review.
6/j.aller.2017.04.006
 and  6  and  a  premature  stop  codon  in  exon  9.  The
ounder  effect  of  this  mutation  in  North  African  patients
ith  group  B  MHC  II  deﬁciency,  had  been  ﬁrst  documented
y  Wiszniewski  et  al.17 The  largest  study  that  conﬁrmed
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0  
he  founder  effect  of  c.  752delG26  mutation  in  34  Tunisian
atients  from  28  families  was  done  by  Ben-Mustapha  et  al.9
nother  large  study  was  performed  on  20  MHC  II  deﬁciency
atients,  out  of  whom  17  patients  harboured  the  com-
on  mutation  752delG26  and  were  originally  from  North
frican  countries.17 The  three  remaining  patients  of  the
atter  study,  in  addition  to  two  more  cases  were  studied  else-
here  revealing  six  mutations  consisting  of  four  homozygous
utations  and  one  patient  with  heterozygous  mutation.18
The  patient  described  here  is  the  ﬁrst  patient  with  p.
188X  mutation  due  to  a  G  to  A  substitution,  leading  to  a
on-functional  RFXANK  gene  product.  This  mutation  is  the
rst  mutation  affecting  exon  3  and  preceding  the  fourth
nkyrin  repeat,  resulting  in  the  truncated  protein  lack-
ng  ankyrin  repeat  4  and  5.  RFX5, the  defected  gene  in
roup  C  patients,  is  located  in  locus  1q21  with  a  12-exon
ranscript.  There  is  a  highly  conserved  DBD  (DNA-binding
omain)  in  RFX5  protein,  located  in  90--166  residues  and
07--614  residues,  which  bind  the  ssDNA  of  the  X-boxes  prior
o  transcription.  Out  of  the  six  mutations  reported  to  now,
ve  mutations  result  in  a  premature  stop  codon  prior  to
he  second  DBD  sequence  and  the  other  one  is  a  missense
utation  substituting  an  arginine  in  a  DNA-binding  surface
equence  which  leads  to  impaired  binding  of  RFX5  to  X-
oxes.
RFXAP,  a  3-exon  gene  located  in  13q14  locus,  was  the
ast  defected  gene  to  be  identiﬁed  in  a  subgroup  of  MHC  II
eﬁciency  patients.  Durand  et  al.  revealed  the  association
f  this  gene  with  MHC  II  deﬁciency  from  an  in  vitro  gener-
ted  mutant,  6.1.6,5 which  was  mutagenised  for  studies  on
ll  antigens  expressed  by  D  locus  of  MHC  II  gene.19 There  is  a
onserved  sequence  at  the  C-terminal  end  of  the  associated
rotein  (140--243  residues)  which  is  responsible  for  bind-
ng  to  DNA.  Five  different  mutations  have  been  discovered
o  now.  Interestingly,  two  unrelated  Turkish  patients  har-
oured  the  same  mutation  and  four  unrelated  North  African
arboured  the  same  c.  delG484fsX525  mutation,  proposing
he  prevalence  of  each  mutation  in  the  associated  region.
our  out  of  ﬁve  reported  mutations  resulted  in  premature
top  codon  prior  to  the  C-terminal  binding  domain  of  RFXAP
rotein.  The  other  reported  mutation  in  a  Turkish  patient
s  a  75  bp  insertion  in  5′-UTR,  leading  to  the  inhibition  of
ranscription.
reatment
ven  though  the  MHC  II  deﬁciency  is  not  as  severe  as  SCID,
ost  patients  fail  to  reach  their  puberty  and  die  of  severe
nfections,  even  on  antibiotic  treatment.  Supportive  care  of
hese  patients  may  help  patients  survive  only  up  to  early
hildhood.10 Patients  with  MHC  II  deﬁciency  who  do  not
ndergo  haematopoietic  stem  cell  transplantation  (HSCT)
uccumb  to  a  complicated  course  and  demise  by  a  median
ge  of  four  to  ﬁve  years.20 Although  HSCT  is  considered  as
he  only  curative  treatment,  studies  show  a  high  rate  of
ost-HSCT  death  because  of  severe  infections,  graft  versus
ost  diseases  (GVHD)  and  organ  failures.10,11,21,22 The  mainPlease  cite  this  article  in  press  as:  Farrokhi  S,  et  al.  MHC  class  II
Allergol  Immunopathol  (Madr).  2017.  http://dx.doi.org/10.101
ause  of  the  poor  outcome  of  HSCT  is  GVHD.  Even  though
he  lymphocytes  of  the  patients  with  MHC  II  deﬁciency  do
ot  express  MHC  II  which  is  required  for  the  rejection  pro-
ess,  the  residual  immunity  is  still  enough  for  developing
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ejection.  The  antigen  presenting  cells  of  the  donor  may
ave  a  role  in  activating  recipient’s  T  cells  and  in  this  regard,
HC  II  deﬁciency  patients  must  have  a  HLA-matched  donor.
Although  studies  found  that  myeloablative  or  reduced
ntensity  conditioning  can  be  used  to  achieve  a  better  post-
ransplant  prognosis,23 Siepermann  et  al.  demonstrated  a
etter  prognosis  in  patients  with  non-myeloablative  precon-
itioning.  This  is  assumed  to  be  associated  with  preservation
f  the  immune  function  against  existing  infections  prior
o  the  transplant.  Renella  et  al.,  reported  a  50%  rate  of
VHDs  higher  than  grade  I  in  14  patients  with  MHC  II  deﬁ-
iency  that  had  undergone  HSCT.24 A  study  on  23  patients
ith  MHC  II  deﬁciency  reported  a rate  of  about  50%  (12/23)
eaths  one  month  to  six  years  after  HSCT,  most  of  which
appened  immediately  after  the  transplant  due  to  severe
VHD  or  severe  infections.10 In  comparison,  seven  out  of
2  patients  on  supportive  care  who  did  not  undergo  HSCT
ere  alive  at  the  end  of  this  study.  Siepermann  et  al.  stud-
ed  68  patients  that  had  been  transplanted,  41  of  whom  were
reconditioned  with  myeloablative  regimen.20 Of  them,  10
atients  developed  graft  rejection  and  42  patients  died  of
VHD  or  severe  infections.  Another  study  on  16  patients
ith  MHC  II  deﬁciency  who  underwent  HSCT  demonstrated
1%  (5/16)  failure  and  37%  (6/16)  GVHD,  during  six  months
fter  HSCT.25 More  recently  Ben-mustapha  et  al.  reported
5%  mortality  in  eight  patients  who  had  undergone  HSCT
ostly  because  of  GVHD,  with  similar  high  rates  of  mortal-
ty  of  70%  in  26  patients  who  had  not  been  transplanted
ostly  because  of  severe  infections.9 Current  literature  on
atients  with  deﬁnitive  diagnosis  of  group  B  MHC  II  deﬁ-
iency  based  on  genetic  analysis  shows  43%  (16/37)  mortality
ollowing  supportive  care,  and  69%  (9/13)  mortality  follow-
ng  HSCT  (Odds  ratio;  2.9,  95%CI  (0.76--11.3),  p  =  0.120).
able  3  demonstrates  detailed  results  on  the  outcome  of
SCT  and  supportive  care  for  patients  with  group  B  MHC
I  deﬁciency.  To  date,  HSCT  confers  no  additional  survival
eneﬁt  over  supportive  care  for  patients  with  group  B  MHC
I  deﬁciency.
Although  the  source  of  stem  cells  required  for  trans-
lantation  was  bone  marrow  in  most  cases,  a  few  studies
eported  umbilical  cord  blood  transplantation  (CBT).  The
xtensive  potency  of  cord  blood  cells  to  differentiate  and
opulate  bone  marrow  with  a  lower  risk  of  contamination
akes  CBT  a  candidate  therapeutic  modality  for  patients
ith  MHC  II  deﬁciency.20 However,  the  drawbacks  of  CBT
re  enormous,  including,  the  high  rate  of  graft  failure  and
he  limitation  of  therapeutic  options  for  the  donor  in  whom
BT  has  been  failed.20 Acute  GVHD,25 poor  engraftment10
nd  remission20 are  frequently  observed  following  CBT  for
atients  with  MHC  II  deﬁciency.  Thus,  if  stem  cell  trans-
lantation  is  planned  to  be  done  for  patients  with  MHC  II
eﬁciency,  HSCT  is  still  superior  on  CBT.
Patients  should  be  observed  carefully  after  HSCT,  because
D4  lymphopenia  may  remain  even  after  transplant  due  to
ack  of  MHC  II  expression  on  thymic  cells.  Before  transplan-
ation,  patients  should  be  on  prophylactic  antibiotics  and
utritional  support  and  receive  intravenous  immunoglobu-
ins  (IVIG)  in  case  of  low  serum  immunoglobulins.  IVIG  and deﬁciency:  Report  of  a  novel  mutation  and  special  review.
6/j.aller.2017.04.006
-CSF  has  been  used  to  increase  serum  immunoglobulin  lev-
ls  and  lymphocyte  counts  but  are  not  curative.  Obviously,
atients  with  MHC  II  deﬁciency  need  improvement  of  ther-
peutic  modalities.  Early  diagnosis  and  treatment  may
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improve  the  outcome  of  patients  with  MHC  II  deﬁciency  by
doing  research  in  upcoming  years.  It  is  to  be  hoped  that
by  better  understanding  the  genetic  background  of  patients
with  MHC  II  deﬁciency,  a  more  efﬁcient  therapeutic  strat-
egy  will  be  developed  which  targets  the  affected  MHC  II
transcriptional  regulatory  factor  genes.
Comment
MHC  II  deﬁciency  is  a  severe  combined  immunodeﬁciency
syndrome  with  a  protracted  course.  Typical  manifestations
include  respiratory  and  gastrointestinal  tract  infections,
diarrhoea,  FTT,  developmental  delay  and  demise  in  early
childhood.  Diagnosis  is  usually  made  by  complete  blood  cell
counts  (CBC),  immunoglobulin  assessment  and  ﬂow  cytom-
etry  which  reveal  decreased  CD4+ counts  and  the  absence
of  MHC  II  expression  by  immune  cells.  Despite  the  clas-
sical  clinical  presentation  and  developed  diagnostic  tools,
the  diagnostic  gap  is  still  an  important  factor  underly-
ing  a  poor  outcome  in  these  children.  The  prevalence  of
MHC  II  deﬁciency  is  highest  in  North  Africa  and  Middle-East
where  low  resources  do  not  allow  for  newborn  screening
for  such  a  primary  immunodeﬁciencies.  In  western  countries
such  as  the  United  States,  screening  for  SCID  has  been
added  to  the  national  newborn  screening  programme  but
it  also  lacks  identiﬁcation  of  MHC  II  deﬁciency  as  a  SCID
related  disorder.26 This  issue  may  be  addressed  by  modiﬁed
newborn  screening  programmes  for  families  with  a  consan-
guineous  marriage  or  history  of  primary  immunodeﬁciency  in
their  ﬁrst-degree  relatives.  Another  problem  here  is  that  an
appropriate  screening  tool  has  not  yet  been  developed  for
MHC  II  deﬁciency.  T-cell  receptor  excision  circles  (TRECs)
which  are  by-products  of  T-cell  receptor  rearrangement  are
used  to  screen  newborns  for  SCID.  Patients  with  MHC  II
deﬁciency  have  T+ combined  immunodeﬁciency  and  current
TREC  cut  points  used  for  SCID  screening  cannot  identify
MHC  II  deﬁciency  as  well.26 The  question  is  now  whether
newborn  screening  for  MHC  II  deﬁciency  is  mandatory  and
cost-effective  in  North-Africa  and  Middle-East  or  not  and  if
so,  how  should  it  be  done.
Conclusion
Herein,  we  described  a  case  of  group  B  MHC  II  deﬁciency
with  a  novel  nonsense  mutation  in  the  third  exon  of  RFXANK,
resulting  in  excision  of  ankyrin  repeats  which  are  responsi-
ble  for  protein--protein  interaction.  The  latter  may  result  in
defected  interaction  of  RFXANK  with  other  Regulatory  fac-
tor  X  family  proteins  which  are  crucial  for  triggering  the
MHC  II  transcription.  The  previously  reported  mutations  in
RFXANK  involve  exon  4--9  and  result  in  lack  of  the  ankyrin
repeats.  The  patient  reported  here  manifested  with  unusual
symptoms;  he  had  developed  recurrent  aphthous  lesions,
dysarthria  and  ataxia.  The  unusual  manifestations  of  the
patient  misled  the  physicians  in  diagnosing  the  disease  and
the  patient  died  of  disseminated  infections,  under  antibiotic
therapy.  The  immunological  ﬁndings  were  the  same  as  otherPlease  cite  this  article  in  press  as:  Farrokhi  S,  et  al.  MHC  class  II
Allergol  Immunopathol  (Madr).  2017.  http://dx.doi.org/10.101
reported  cases  and  consisted  of  CD4+ lymphopenia,  reversed
CD4/CD8  ratio  and  decreased  IgA  concentration.  We  have
provided  a  review  of  the  reported  MHC  II  deﬁciency  cases
to  help  understanding  of  the  spectrum  of  epidemiological, PRESS
11
linical,  immunological  and  genetic  characteristics  of  the
HC  II  deﬁciency  disease  and  the  therapeutic  outcomes.
he  diagnostic  gap  and  the  misleading  nature  of  the  dis-
ase  may  be  the  main  reasons  for  the  poor  outcome  of  MHC
I  deﬁciency  patients.
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